TY - JOUR
T1 - Successful treatment of a 2-year-old girl with intractable myasthenia gravis using tacrolimus
AU - Kakisaka, Yosuke
AU - Haginoya, Kazuhiro
AU - Yokoyama, Hiroyuki
AU - Ishitobi, Mamiko
AU - Wakusawa, Keisuke
AU - Sato, Ikuko
AU - Togashi, Noriko
AU - Kitamura, Taro
AU - Fukuyo, Naomi
AU - Yoshihara, Yasushi
AU - Iinuma, Kazuie
PY - 2006/9
Y1 - 2006/9
N2 - We used tacrolimus to successfully treat a patient with childhood-onset oropharyngeal myasthenia gravis (MG). A girl (2 years, 5 months old) with oropharyngeal MG responded partially to treatment including pyridostigmine bromide, intravenous immunoglobulin, and prednisolone (2 mg/kg/day) for 7 weeks, but this resulted in worsening of her eye symptoms. By contrast, tacrolimus at 2 mg/day resulted in complete remission of the MG, which made it possible to reduce the dose of prednisolone. This is a rare report of the use of tacrolimus as an effective treatment for patients with intractable childhood-onset MG.
AB - We used tacrolimus to successfully treat a patient with childhood-onset oropharyngeal myasthenia gravis (MG). A girl (2 years, 5 months old) with oropharyngeal MG responded partially to treatment including pyridostigmine bromide, intravenous immunoglobulin, and prednisolone (2 mg/kg/day) for 7 weeks, but this resulted in worsening of her eye symptoms. By contrast, tacrolimus at 2 mg/day resulted in complete remission of the MG, which made it possible to reduce the dose of prednisolone. This is a rare report of the use of tacrolimus as an effective treatment for patients with intractable childhood-onset MG.
KW - Childhood
KW - Immunosuppressant
KW - Myasthenia gravis
KW - Tacrolimus
UR - http://www.scopus.com/inward/record.url?scp=33745912232&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745912232&partnerID=8YFLogxK
U2 - 10.1016/j.braindev.2006.02.001
DO - 10.1016/j.braindev.2006.02.001
M3 - Article
C2 - 16564661
AN - SCOPUS:33745912232
SN - 0387-7604
VL - 28
SP - 534
EP - 536
JO - Brain and Development
JF - Brain and Development
IS - 8
ER -